The head of Spain's Grifols is optimistic his company's $4 billion takeover of Talecris Biotherapeutics will win approval from U.S. antitrust regulators.
Grifols and Talecris, which is based in Research Triangle Park, both make medicines from blood plasma. The Federal Trade Commission is reviewing the proposed union to make sure it doesn't lead to higher prices for such drugs. The FTC blocked an earlier Talecris takeover by an Australian company because of antitrust concerns.
“I have in my bag $4 billion sitting and waiting to be invested,” CEO Victor Grifols said at an event in Madrid, Bloomberg News reported. “I don’t know when we’ll receive the green light from the FTC. I’m sure we’ll get it, but it’s a very long process. As soon as we get approval we are going to invest it.”
Grifols and Talecris have extended the deadline for their deal to June 30, which would be more than a year after it was announced.
The fact that Grifols' CEO is discussing it suggests an FTC decision could be coming soon.